Table 2. Univariate prognostic analysis of DFS and OS.
| Characteristics | DFS | OS | ||
| Estimated mean survival(months) | P value | Estimated mean survival (months) | P value | |
| AJCC T Stage | 0.492 | 0.567 | ||
| 1 | 87.8 | 94.8 | ||
| 2 | 82.3 | 91.1 | ||
| 3–4 | 63.0 | 74.0 | ||
| AJCC N Stage | 0.908 | 0.558 | ||
| 0 | 85.8 | 93.8 | ||
| 1 | 82.2 | 92.4 | ||
| 2 | 72.9 | 76.4 | ||
| 3 | 69.0 | 74.8 | ||
| Grade | 0.097 | 0.525 | ||
| 1 | 92.1 | 94.4 | ||
| 2 | 80.2 | 92.0 | ||
| 3 | 73.8 | 82.6 | ||
| ER | 0.008* | 0.008* | ||
| Positive | 89.2 | 96.0 | ||
| Negative | 73.2 | 84.1 | ||
| PR | 0.014* | 0.031* | ||
| Positive | 90.9 | 96.8 | ||
| Negative | 76.0 | 86.9 | ||
| HER2 | 0.145 | 0.148 | ||
| Negative | 85.9 | 93.4 | ||
| Positive | 69.8 | 79.8 | ||
| Subtype | 0.003* | 0.018* | ||
| LA | 91.8 | 97.9 | ||
| LB | 84.9 | 91.5 | ||
| TN | 77.0 | 85.7 | ||
| HER2+ | 53.1 | 68.0 | ||
| CHD1L over-expression | 0.035* | 0.439 | ||
| Absense | 88.5 | 90.7 | ||
| Presence | 78.9 | 95.5 | ||
*, statistically significant.
Abbreviations: DFS, disease free survival; OS, overall survival; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; LA, luminal A; LB, luminal B; TN, triple negative.